alpelisib 50 MG 28 Day Pack

RxCUI: 2598466
RxNorm name: alpelisib 50 MG 28 Day Pack
Display name: alpelisib 50 MG 28 Day Pack
Full name: alpelisib 50 MG 28 Day Pack
Term type: PSN
Status: DailyMed mapping
Updated: 2026-06-04 23:39:01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
VIJOICE	ALPELISIB	Novartis Pharmaceuticals Corporation	638069a4-aee0-46c9-9e21-54ad449c163c	2025-11-04	Warnings, Adverse reactions	Exact identifier rxcui: 2598466

DailyMed RxNorm Mappings#

Set ID, RxNorm string, TTY table
Set ID	RxNorm string	TTY	SPL version	Label	Effective
638069a4-aee0-46c9-9e21-54ad449c163c	alpelisib 50 MG 28 Day Pack	PSN	10	These highlights do not include all the information needed to use VIJOICE safely and effectively. See full prescribing information for VIJOICE. VIJOICE ® (alpelisib) tablets, for oral use VIJOICE ® (alpelisib) oral granules Initial U.S. Approval: 2019	20251104
638069a4-aee0-46c9-9e21-54ad449c163c	{28 (alpelisib 50 MG Oral Tablet) } Pack	GPCK	10	These highlights do not include all the information needed to use VIJOICE safely and effectively. See full prescribing information for VIJOICE. VIJOICE ® (alpelisib) tablets, for oral use VIJOICE ® (alpelisib) oral granules Initial U.S. Approval: 2019	20251104
638069a4-aee0-46c9-9e21-54ad449c163c	alpelisib 50 MG 28 Day Pack	SY	10	These highlights do not include all the information needed to use VIJOICE safely and effectively. See full prescribing information for VIJOICE. VIJOICE ® (alpelisib) tablets, for oral use VIJOICE ® (alpelisib) oral granules Initial U.S. Approval: 2019	20251104